Cancer scene investigation: How a cold virus became a tumor killer

Future Oncology

Volumn 1, Issue 2, 2005, Pages 247-258

  Post, Dawn E ^a   Shim, Hyunsuk ^a   Toussaint Smith, Esra ^a   Van Meir, Erwin G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adenovirus; gene therapy; oncolytic therapy; oncolytic virus; tumors; virotherapy

Indexed keywords

ONCOLYTIC VIRUS;

FORECASTING; HUMAN; NEOPLASM; ONCOLYTIC VIROTHERAPY; PHYSIOLOGY; REVIEW; VIROLOGY; VIRUS REPLICATION;

FORECASTING; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

EID: 33646461175     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.1517/14796694.1.2.247     Document Type: Review

References (65)

1. Raper SE, Chirmule N, Lee FS et al.: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80, 148-158 (2003)
2. Kanerva A, Hemminki A: Modified adenoviruses for cancer gene therapy. Int. J. Cancer 110, 475-480 (2004)
3. Everts M, Curiel DT: Transductional targeting of adenoviral cancer gene therapy. Curr. Gene Ther. 4, 337-346 (2004)
4. Chu RL, Post DE, Khuri FR, Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin. Cancer Res. 10, 5299-5312 (2004)
5. Dobbelstein M: Replicating adenoviruses in cancer therapy. Curr. Top. Microbiol. Immunol. 273291-27334 (2004)
6. Post DE, Van Meir EG: A novel hypoxiainducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22, 2065-2072 (2003)
7. Post DE, Devi NS, Li Z et al.: Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin. Cancer Res. 10, 8603-8612 (2004)
8. Holm PS, Bergmann S, Jurchott K et al.: YB- 1 relocates to the nucleus in adenovirusinfected cells and facilitates viral replication by inducing E2 gene expression through the E2 late promoter. J. Biol. Chem. 277, 10427-10434 (2002)
9. Holm PS, Lage H, Bergmann S et al.: Multidrug-resistant cancer cells facilitate E1-independent adenoviral replication: impact for cancer gene therapy. Cancer Res. 64, 322-328 (2004)
10. Haviv YS, Blackwell JL, Kanerva A et al.: Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res. 62, 4273-4281 (2002)
11. Shinoura N, Yoshida Y, Tsunoda R et al.: Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59, 3411-3416 (1999)
12. Suzuki K, Fueyo J, Krasnykh V et al.: A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7, 120-126 (2001)
13. Barnett BG, Crews CJ, Douglas JT: Targeted adenoviral vectors. Biochim. Biophys. Acta 1575, 1-14 (2002)
14. Green NK and Seymour LW: Adenoviral vectors: systemic delivery and tumor targeting. Cancer Gene Ther. 9, 1036-1042 (2002)
15. Fisher KD, Stallwood Y, Green NK et al.: Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341-348 (2001)
16. Maeda M, Kida S, Hojo K et al.: Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg. Med. Chem. Lett. 15, 621-624 (2005)
17. Bischoff JR, Kirn DH, Williams A et al.: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996)
18. Goodrum FD, Ornelles DA: p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72, 9479-9490 (1998)
19. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS: Functions and mechanisms of action of the adenovirus E3 proteins. Int. Rev. Immunol. 23, 75-111 (2004)
20. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR: The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200-4203 (1999)
21. Suzuki K, Alemany R, Yamamoto M, Curiel DT: The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res. 8, 3348-3359 (2002)
22. Doronin K, Toth K, Kuppuswamy M et al.: Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147-6155 (2000)
23. Doronin K, Toth K, Kuppuswamy M et al.: Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology 305, 378-387 (2003)
24. Sauthoff H, Hu J, Maca C et al.: Intratumoral spread of wild-type adenovirus is limited after local injection of human xenograft tumors: virus persists and spreads systemically at late time points. Hum. Gene Ther. 14, 425-433 (2003)
25. Wang Y, Hallden G, Hill R et al.: E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nature Biotechnol. 21, 1328-1335 (2003)
26. Hawkins LK, Johnson L, Bauzon M et al.: Gene delivery from the E3 region of replicating human adenovirus: evaluation of the 6.7 K/gp19 K region. Gene Ther. 8, 1123-1131 (2001)
27. Rogulski KR, Freytag SO, Zhang K et al.: In vivo anti-tumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193-1196 (2000)
28. Geoerger B, Grill J, Opolon P et al.: Oncolytic activity of the E1B-55 kDadeleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62, 764-772 (2002)
29. Petit T, Davidson KK, Cerna C et al.: Efficient induction of apoptosis by ONYX- 015 adenovirus in human colon cancer cell lines regardless of p53 status. Anticancer Drugs 13, 47-50 (2002)
30. Ries SJ, Brandts CH, Chung AS et al.: Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nature Med. 6, 1128-1133 (2000)
31. O'Shea C C, Johnson L, Bagus B et al.: Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611-623 (2004)
32. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, and Kim JH: A novel threepronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum. Gene Ther. 9, 1323-1333 (1998)
33. Rodriguez R, Schuur ER, Lim HY et al.: Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigenpositive prostate cancer cells. Cancer Res. 57, 2559-2563 (1997)
34. Heise C, Sampson-Johannes A, Williams A et al.: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and anti-tumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature Med. 3, 639-645 (1997)
35. Yver A: Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication? J. Clin. Oncol. 19, 3155-3157 (2001)
36. Wadler S, Yu B, Tan JY, et al.: Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants. Clin. Cancer Res. 9, 33-43 (2003)
37. Stegman LD, Rehemtulla A, Hamstra DA et al.: Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther. 7, 1005-1010 (2000)
38. Blasberg R: PET imaging of gene expression. Eur. J. Cancer 38, 2137-2146 (2002)
39. Jacobs A, Voges J, Reszka R, et al.: Positron-emission tomography of vectormediated gene expression in gene therapy for gliomas. Lancet 358, 727-729 (2001)
40. Ponomarev V, Doubrovin M, Serganova I et al.: A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur. J. Nucl. Med. Mol. Imaging 31, 740-751 (2004)
41. Hamstra DA, Lee KC, Tychewicz JM et al.: The use of 19F spectroscopy and diffusionweighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol. Ther. 10, 916-928 (2004)
42. Heise C, Hermiston T, Johnson L et al.: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Med. 6, 1134-1139 (2000)
43. Fueyo J, Gomez-Manzano C, Alemany R et al.: A mutant oncolytic adenovirus targeting the Rb pathway produces anti- glioma effect in vivo. Oncogene 19, 2-12 (2000)
44. Semenza GL: Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003)
45. Ganly I, Kirn D, Eckhardt G et al.: A Phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806 (2000)
46. Mulvihill S, Warren R, Venook A et al.: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replicationselective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther. 8, 308-315 (2001)
47. Reid T, Galanis E, Abbruzzese J et al.: Intraarterial administration of a replicationselective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a Phase I trial. Gene Ther. 8, 1618-1626 (2001)
48. Habib NA, Sarraf CE, Mitry RR et al.: E1Bdeleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. Hum. Gene Ther. 12, 219-226 (2001)
49. Nemunaitis J, Cunningham C, Buchanan A et al.: Intravenous infusion of a replicationselective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746-759 (2001)
50. Nemunaitis J, Cunningham C, Tong AW et al.: Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX- 015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 10, 341-352 (2003)
51. Vasey PA, Shulman LN, Campos S et al.: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569 (2002)
52. Chiocca EA, Abbed KM, Tatter S et al.: A Phase I Open-Label, Dose-Escalation, Multi-Institutional Trial of Injection with an E1B-Attenuated Adenovirus, ONYX- 015, into the Peritumoral Region of Recurrent Malignant Gliomas, in the Adjuvant Setting. Mol. Ther. 10, 958-966 (2004)
53. Rudin CM, Cohen EE, Papadimitrakopoulou VA et al.: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin. Oncol. 21, 4546-4552 (2003)
54. DeWeese TL, van der Poel H, Li S et al.: A Phase I trial of CV706, a replicationcompetent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472. (2001)
55. Freytag SO, Khil M, Stricker H et al.: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62, 4968-4976 (2002)
56. Freytag SO, Stricker H, Pegg J et al.: Phase I study of replication-competent adenovirusmediated double-suicide gene therapy in combination with conventional-dose threedimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 63, 7497-7506 (2003)
57. Nemunaitis J, Ganly I, Khuri F et al.: Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B- 55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res. 60, 6359-6366 (2000)
58. Nemunaitis J, Khuri F, Ganly I et al.: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289-298 (2001)
59. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, and McCarty TM: A prospective Phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann. Surg. Oncol. 7, 588-592. (2000)
60. Khuri FR, Nemunaitis J, Ganly I et al.: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5- fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879-885. (2000)
61. Hecht JR, Bedford R, Abbruzzese JL et al.: A Phase I/II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX- 015 with Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma. Clin. Cancer Res. 9, 555-561 (2003)
62. Makower D, Rozenblit A, Kaufman H et al.: Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. Clin. Cancer Res. 9, 693-702 (2003)
63. Reid T, Galanis E, Abbruzzese J et al.: Hepatic arterial infusion of a replicationselective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070-6079 (2002)
64. Hamid O, Varterasian ML, Wadler S et al.: Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 1498-1504 (2003)
65. Morley S, MacDonald G, Kirn D et al.: The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma. Clin. Cancer Res. 10, 4357-4362 (2004). 101 www.onyx-pharm.com (Accessed March 2005)